Coronavirus / COVID

Novavax, Inc has unveiled promising results regarding its JN1 COVID-19 vaccine's efficacy against emerging virus variants, including KP2 and KP3.

Biosurveillance has evolved beyond biodefense, emphasizing a comprehensive network to detect and counter biological threats.

During today's CDC Advisory Committee on Immunization Practices (ACIP) meeting, committee members voted to recommend the FDA-authorized 2024-2025 COVID-19 vaccines for individuals aged 6 months and older. Additionally, they reaffirmed the existing influenza vaccination guidelines for the 2024-2025 season.

Those individuals who received older versions of vaccines did not see significantly reduced risks of severe COVID-19 outcomes.

Research presented at ASHP 2024 found that concerns around the safety of COVID-19 vaccines and the credibility of information from public health authorities were the biggest drivers of vaccine hesitancy during the COVID-19 pandemic.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

Jerry Krishnan, MD, PhD, working with NASEM, examines the multifaceted challenges of defining Long COVID as they introduce a unified definition for this persistent condition.

Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.

The state's attorney general filed the lawsuit against Pfizer for its ‘misleading statements’ about the vaccine.

In response to evolving data on SARS-CoV-2 strains and rising COVID-19 cases, the FDA advises vaccine manufacturers to explore incorporating the KP2 strain into the upcoming 2024-2025 COVID-19 vaccine formula.

Leveraging Evie Ring technology, the collaboration seeks to enhance understanding and develop strategies for managing these illnesses.

A recently published secondary analysis sought to evaluate the risk of MACE in those patients who received one or two doses of the COVID-19 following acute coronary syndromes.

With no observed mortality or adverse outcomes, this research sheds light on effective treatments for combating the pandemic in younger populations.

Exact estimates of hospitalization and fatality rates for SARS-CoV-2 are rare among populations without previous exposure, particularly within demographic subgroups.

The company announced data this morning for its investigational mRNA-1083 vaccine and plans to continue collecting data and working towards submitting a Biological License Application (BLA) for it.

A newly published study suggests that a 15-day regimen, while safe, did not statistically separate from a placebo comparator group in main outcomes for PASC of SARS-CoV-2 infection.

Although there is a rise in the FLiRT family of mutations, the committee decided to seek protection against the older strain.

While much attention has been focused on the immediate risks of the virus during pregnancy, this study is focused on what happens to pregnant individuals after they have had COVID-19.

Deaths varied greatly depending on the age group, with the oldest population having the highest rates.

Research reveals a surge in pressure ulcers and in-hospital mortality rates during peak pandemic periods, prompting calls for strategies to safeguard care quality.

Recent study examines the relationship between COVID-19 vaccination and post-COVID conditions, shedding light on the potential long-term effects of vaccination.

Recent study sheds light on potential mechanisms underlying severe lung damage in COVID-19 patients.

A study shows the definitive presence of the virus long-term in individuals and could point to lingering symptoms and the possibility of Long COVID.

A new study demonstrates that for last year’s respiratory season, the difference in death rates were still much higher for COVID-19, but the gap closed significantly from the year before.

North Carolina’s senate voted to repeal the health exemption of the existing mask wearing law, thus disallowing any exceptions for people to wear a mask across the state.

A large study on the future directions unveiling COVID-19 vaccine safety and risks.

SCORPIO-HR trial findings on ensitrelvir's role in managing COVID-19 amid regulatory hurdles.

From July to November 2021, cruise ships accommodating COVID-19-vaccinated individuals implemented almost identical nonpharmaceutical protocols.

The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.

This study, presented at MAD-ID, The Antimicrobial Stewardship Meeting, evaluates patients with mild COVID-19 symptoms compared to those with severe cases.